Kolon TissueGene, Inc. (KOSDAQ:950160)
17,940
+320 (1.82%)
Sep 1, 2026, 3:30 PM KST
Kolon TissueGene Revenue
Kolon TissueGene had revenue of 1.41B KRW in the quarter ending March 31, 2026, with 9.49% growth. This brings the company's revenue in the last twelve months to 5.28B, up 2.95% year-over-year. In the year 2025, Kolon TissueGene had annual revenue of 5.16B with 1.68% growth.
Revenue (ttm)
5.28B
Revenue Growth
+2.95%
P/S Ratio
288.65
Revenue / Employee
182.10M
Employees
29
Market Cap
1.52T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.16B | 85.27M | 1.68% |
| Dec 31, 2024 | 5.07B | 1.37B | 36.90% |
| Dec 31, 2023 | 3.71B | -5.75B | -60.81% |
| Dec 31, 2022 | 9.46B | 5.45B | 136.22% |
| Dec 31, 2021 | 4.00B | 447.31M | 12.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.31T |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 125.87B |
| Onconic Therapeutics | 82.17B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| OliX Pharmaceuticals | 17.26B |
Kolon TissueGene News
- 18 days ago - Kolon TissueGene Quarterly report: Q2 2026 - Filings
- 3 months ago - Kolon TissueGene Quarterly report: Q1 2026 - Filings
- 5 months ago - Kolon TissueGene Annual report: Q4 2025 - Filings
- 10 months ago - Kolon TissueGene Quarterly report: Q3 2025 - Filings